NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA
Revista Científica Ipedss · 2026 · 06 (03)
DOI: 10.55703/27644006060304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Científica Ipedss, 2026. Verfasst von Danilo Gustavo Gonçalves Ferreira Romanelli und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To analyze the effects of glucagon-like peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and triple GIP/GLP-1/glucagon receptor agonists on body weight reduction, type 2 diabetes mellitus control, and the main systemic outcomes associated with obesity.
Methods
An integrative literature review was conducted using PubMed/MEDLINE, with complementary searches in Scopus, Web of Science, Embase, the Cochrane Library, and ClinicalTrials.gov. Primary studies published between January 2015 and July 2026 were included if they involved adults with obesity, overweight, type 2 diabetes, or adiposity-related complications. Phase II and III randomized clinical trials, cardiovascular and renal outcome trials, long-term extensions, and clinically relevant substudies were prioritized. The final sample comprised 35 studies, including 17 on liraglutide or semaglutide, 14 on tirzepatide, and four on retatrutide.
Results
Liraglutide produced mean weight reductions of approximately 6% to 8%, whereas semaglutide 2.4 mg achieved reductions close to 15% in individuals without diabetes. Tirzepatide resulted in weight loss exceeding 20% in people with obesity without diabetes and produced substantial glycated hemoglobin reductions in patients with type 2 diabetes. Retatrutide achieved weight loss of up to 24.2% in a phase II trial and confirmed marked glycemic and weight-reduction efficacy in a phase III study. Semaglutide reduced cardiovascular and renal events and improved outcomes related to heart failure, osteoarthritis, and metabolic liver disease. Tirzepatide showed favorable effects on heart failure, obstructive sleep apnea, metabolic steatohepatitis, and progression from prediabetes to type 2 diabetes. Gastrointestinal adverse events were the most frequently reported, particularly during dose escalation. Withdrawal trials demonstrated substantial weight regain after treatment discontinuation.
Conclusion
The transition from isolated GLP-1 receptor agonism to dual and triple receptor agonism has substantially increased the efficacy of obesity pharmacotherapy. Semaglutide and tirzepatide have consistent evidence supporting metabolic and systemic benefits, whereas retatrutide remains a promising investigational therapy that requires further confirmation of long-term safety and cardiovascular and renal effectiveness. Treatment should be individualized, continuous, and combined with nutritional, behavioral, and functional interventions. Keywords: Obesity; Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes Mellitus; Weight Loss; Cardiometabolic Diseases.
Zitieren
APA
Romanelli, D. G. G. F., & Romanelli, A. C. F. S. (2026). NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA. Revista Científica Ipedss, 06(03). https://doi.org/10.55703/27644006060304
Vancouver
Romanelli DGGF, Romanelli ACFS. NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA. Revista Científica Ipedss. 2026;06(03). doi:10.55703/27644006060304
BibTeX
@article{Romanelli2026,
author = {Romanelli, Danilo Gustavo Gonçalves Ferreira and Romanelli, Ana Cristina Faria Silva},
title = {NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA},
journal = {Revista Científica Ipedss},
year = {2026},
volume = {06},
number = {03},
doi = {10.55703/27644006060304}
}
EUVIMED